Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZBG regimen in treatment-naïve follicular lymphoma
ChiCTR2500106844Phase 4Not yet recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Jul 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zanubrutinib, obinutuzumab and bendamustine in follicular lymphoma (FL), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Complete response rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
zanubrutinibobinutuzumabbendamustine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2500106844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106844.